Related Experiment Videos
Cardiomyocyte transplantation does not reverse cardiac remodeling in rats with chronic myocardial infarction
Yutaka Sakakibara1, Keiichi Tambara, Fanglin Lu
1Department of Cardiovascular Surgery, Kyoto University, Graduate School of Medicine, Japan.
Insights
Fetal cardiomyocyte transplantation in rats with chronic myocardial infarction prevented cardiac remodeling and heart failure. However, it did not reverse existing damage, suggesting further research is needed for clinical application.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Cell transplantation shows promise as an alternative to cardiac transplantation.
- Chronic myocardial infarction leads to left ventricular dysfunction and heart failure.
Purpose of the Study:
- To investigate the efficacy of fetal cardiomyocyte transplantation in rats with chronic myocardial infarction.
- To assess the impact of cell transplantation on cardiac remodeling and function.
Main Methods:
- Rats with induced chronic myocardial infarction underwent echocardiography to confirm left ventricular dysfunction.
- Rats were randomized to receive fetal cardiomyocyte transplantation or a control injection.
- Cardiac function and histology were evaluated four weeks post-treatment.
Main Results:
- The cardiomyocyte transplantation group showed improved end-systolic dimension and fractional shortening compared to controls.
- No significant changes in LV end-diastolic dimension or fractional shortening were observed from baseline within the treatment group.
- Microscopic analysis revealed transplanted cells in the peri-infarct region, with a thicker ventricular wall in the infarct area.
Conclusions:
- Fetal cardiomyocyte transplantation prevented cardiac remodeling associated with heart failure in myocardial infarction rats.
- The treatment did not reverse existing cardiac damage.
- Further research is necessary to optimize cell transplantation for clinical use in failing hearts.
Background:
Several reports have documented the potential benefits of cell transplantation as an alternative to cardiac transplantation. This study was designed to investigate whether cardiomyocyte transplantation is effective in rats with chronic myocardial infarction.
Methods:
Syngeneic Lewis rats were used in this study. Chronic myocardial infarction was induced in rats by ligating the left anterior descending artery. Four weeks later, after left ventricular (LV) dysfunction with akinetic regions was confirmed by echocardiography, the rats were randomized into two groups: a group that received fetal cardiomyocyte transplantation (TX group; n = 11); and a group that received an intramyocardial injection of culture medium only (control group; n = 12).
Results:
Four weeks after treatment, the TX group had smaller end-systolic dimension (LVDs) (7.5 +/- 0.9 vs 8.9 +/- 0.8 mm, p < 0.01) and better fractional shortening (FS) (26.2 +/- 5.9 vs 17.7% +/- 5.1%, p < 0.01) than the control group. However, there were no differences in LV end-diastolic dimension, LVDs, and FS between baseline and post-treatment values in the TX group. In addition, plasma levels of atrial natriuretic peptide were not significantly different between the two groups 4 weeks after treatment. In microscopic examination, small amounts of transplanted cardiomyocytes were found only in the periinfarct area, not in the center of scar area, and a thicker ventricular wall in the infarct area was detected in the TX group.
Conclusions:
Fetal cardiomyocyte transplantation prevented, but did not reverse, cardiac remodeling that was accompanied with heart failure in myocardial infarction rats. Further investigation is warranted for optimal clinical application to the failing heart.